The Egyptian Liver Journal, ISSN 2090-6218, is a vital resource for the hepatology community, published by SPRINGEROPEN. Since its establishment in 2012, this journal has served as a platform for disseminating significant findings in liver research, with an emphasis on enhancing understanding and treatment of liver diseases. Recognized with a Q3 ranking in Hepatology for 2023, the Egyptian Liver Journal aims to bridge the gap between research and clinical practice through its commitment to open access, fostering a global exchange of knowledge without barriers since 2019. With a focus on innovative studies, reviews, and clinical guidelines, the journal appeals to a diverse audience of researchers, clinicians, and students dedicated to advancing liver health. Situated in the heart of the United States, this publication addresses the pressing issues within the field and encourages submissions that address the future of liver care and treatment.

HEPATOLOGY is a premier scholarly journal dedicated to advancing the field of liver research and clinical practice. Published by Lippincott Williams & Wilkins, this journal boasts an impressive impact factor and holds a prestigious position as one of the top-ranked publications in both Hepatology (Q1) and Medicine (miscellaneous, Q1) categories as of 2023. HEPATOLOGY, with its commitment to disseminating high-quality research since its inception in 1981, serves as an essential platform for researchers, clinicians, and students focusing on liver diseases, including hepatitis, cirrhosis, and liver cancer. The journal's editorial board comprises leading experts who guide the publication towards its objective of fostering innovation and collaboration in this critical area of health. Although it does not offer an open access model, HEPATOLOGY ensures that its comprehensive analyses, reviews, and groundbreaking studies are accessible to the global medical community. Join the discourse in hepatology and be a part of a transformative journey through this indispensable resource.

Expert Review of Gastroenterology & Hepatology is a premier journal published by Taylor & Francis Ltd that aims to bridge the gap between clinical practice and research in the fields of gastroenterology and hepatology. Established in 2007, this journal has rapidly gained recognition, boasting a Q1 ranking in Gastroenterology and a Q2 ranking in Hepatology for 2023, while achieving impressive Scopus rankings of 31st and 25th respectively in these disciplines, placing it within the top 81st and 70th percentiles. The journal’s objective is to provide a comprehensive platform for the latest developments, innovative treatments, and critical reviews, catering to researchers, healthcare professionals, and students alike. Located in the United Kingdom, the journal does not operate under an open access model but ensures that its content is accessible to a global audience through institutional subscriptions. By consistently publishing high-impact reviews and articles, Expert Review of Gastroenterology & Hepatology solidifies its role as a vital resource in advancing knowledge and clinical practice within these challenging and evolving fields.

Hepatic Medicine-Evidence and Research is a distinguished open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing knowledge in the field of hepatology. Since its inception in 2009, this journal has served as a critical platform for researchers, professionals, and students alike, facilitating the dissemination of high-quality, peer-reviewed articles that address the latest developments in hepatic medicine. With a commitment to accessibility, all articles are freely available to a global audience, thereby promoting collaboration and innovation in research. Although specific metrics such as H-index and Scopus ranks are currently undeclared, the journal is recognized for its contributions to clinical practice and ongoing research in liver health, making it an essential resource for those seeking to enhance their understanding of hepatic conditions and treatments. By prioritizing the latest evidence and research in this vital field, Hepatic Medicine-Evidence and Research continues to play a pivotal role in influencing clinical outcomes and shaping future studies.

Hepatobiliary & Pancreatic Diseases International, an esteemed journal published by Elsevier, stands as a vital resource within the field of gastroenterology and hepatology. Established in 2002, this journal has developed a significant reputation, currently ranked in the second quartile (Q2) in both categories as of 2023, showcasing its commitment to high-quality research and clinical studies. Based in Singapore, Hepatobiliary & Pancreatic Diseases International serves as an essential platform for researchers, clinicians, and healthcare professionals to share innovative findings, therapeutic approaches, and advancements in the understanding of hepatobiliary and pancreatic diseases. Although the journal does not currently offer Open Access, its rigorous peer-review process ensures that published articles maintain the highest scientific standards, fostering knowledge dissemination among the global research community. With a convergence period extending to 2024, this journal continues to play a pivotal role in enhancing the understanding and treatment of complex gastrointestinal conditions, making it a must-read for anyone engaged in this dynamic field.

Hepatology Forum is an esteemed journal dedicated to disseminating cutting-edge research and insights in the fields of gastroenterology and hepatology. Published by KARE PUBL in Turkey, this journal serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to advance their knowledge and practices related to liver diseases and gastrointestinal disorders. With an ISSN of 1307-5888 and an E-ISSN of 2757-7392, it features peer-reviewed articles that encompass a wide range of topics from basic research to clinical applications. Although categorized in the Q3 quartile for both gastroenterology and hepatology in 2023, Hepatology Forum continues to show significant potential for growth and impact, as evidenced by its Scopus rankings. Through its commitment to open scientific exchange, the journal not only facilitates the sharing of innovative methodologies and findings but also fosters networking among professionals in the field. As it converges through the years from 2020 to 2024, Hepatology Forum remains an important resource for the advancement of liver health and diseases, appealing to both established experts and emerging scholars alike.

Liver Cancer is a premier, peer-reviewed journal dedicated to the comprehensive study and advancement of knowledge surrounding liver neoplasms. Published by KARGER and headquartered in Switzerland, this journal has been an open-access platform since 2012, providing researchers with invaluable insights into the rapidly evolving field of hepatology and oncology. With an impressive impact factor that places it in the Q1 category for both Hepatology and Oncology in 2023, Liver Cancer stands out as a high-impact conduit for groundbreaking research, ranking #19 out of 404 in Medicine _ Oncology and #6 out of 82 in Medicine _ Hepatology according to Scopus. Researchers, practitioners, and students are encouraged to engage with the journal's content, which encompasses clinical studies, basic research, and reviews that contribute significantly to understanding liver cancer dynamics, diagnosis, and treatment strategies. This journal not only facilitates the dissemination of knowledge but also fosters collaboration in a well-established and impactful global scientific community.

Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.

DIGESTIVE DISEASES, published by KARGER, stands as a leading international journal dedicated to the field of gastroenterology and digestive health. With an ISSN of 0257-2753 and E-ISSN 1421-9875, the journal has been providing a platform for high-quality research since its inception in 1983, continuing to disseminate groundbreaking findings and insights through to 2024. Positioned in the second quartile (Q2) of both the gastroenterology and miscellaneous medicine categories as of 2023, DIGESTIVE DISEASES is recognized for its rigorous peer-review process and its contributions to advancing clinical and experimental gastroenterological knowledge. Its Scopus ranking at #62 out of 167 in the gastroenterology field reflects its significant impact, as it reaches a notable 63rd percentile among its peers. While it does not currently offer open access options, its subscription model ensures that vital research is available to professionals and institutions committed to the field. The journal serves as an essential resource for researchers, clinicians, and students alike who seek to deepen their understanding of digestive disorders and their implications in medicine.

Gastroenterologia y Hepatologia, published by Elsevier España SLU, is a distinguished journal dedicated to advancing the fields of gastroenterology and hepatology. With a publication history spanning from 1982 to 2024, this journal is recognized for its commitment to disseminating high-quality research and reviews that address critical developments in the diagnosis and treatment of gastrointestinal and liver diseases. Although it currently ranks in the Q3 quartile in both gastroenterology and hepatology based on the 2023 metrics, the journal continues to attract a global audience of researchers, healthcare professionals, and students eager to engage with the latest findings. The journal is accessible in both print and electronic formats (ISSN: 0210-5705), making its valuable insights reachable to a broad spectrum of subscribers. By fostering a platform for rigorous scholarly communication, Gastroenterologia y Hepatologia plays a vital role in shaping the future of research in these essential medical fields.